L-aspartic acid as a formulation-enabled platform: translational opportunities in programmable drug delivery systems

L-Aspartic acid (L-Asp) is an endogenous amino acid with physicochemical properties relevant to pharmaceutical formulation design. Its ionization behavior, coordination capacity, and chemical derivatization support several formulation functions. However, free L-Asp is an endogenous and readily metabolized molecule, which limits exposure control, tissue residence, and sustained performance when administered without a formulation. Its pharmaceutical value emerges from molecular derivatization and formulation engineering rather than from the biological activity of the free molecule itself. In this review, we evaluate L-Asp-derived and poly(aspartic acid) (PAsp)-based systems from a formulation-centered perspective and differentiate the biological characteristics of free L-Asp from the emergent properties of L-Asp-derived and PAsp-derived materials. Moreover, we discuss the pharmaceutical outcomes enabled by formulation design and representative platforms, including salt and co-amorphous systems, PAsp-based carriers and hydrogels, targeted and stimuli-responsive systems, and biomaterial- or mineral-interactive systems. In this review, we benchmark L-Asp-derived and PAsp-derived systems against established delivery materials and assess formulation functions, potential advantages, common limitations, and evidence requirements for translational positioning. Development-related considerations, including stability, manufacturability, quality attributes, safety, and route-specific performance, are further discussed. Overall, free L-Asp, L-Asp-derived materials, and PAsp-based platforms should be regarded as related but distinct formulation entities. Their pharmaceutical value depends on rational molecular modifications, appropriate system architecture, and application-specific formulation design.